Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1073-P ◽  
Author(s):  
JULIO ROSENSTOCK ◽  
ANTONIO J. NINO ◽  
JOSEPH SOFFER ◽  
JASON M. MALLORY ◽  
LOIS M. ERSKINE ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Prandial Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

PaQ®, a simple 3-day basal/bolus insulin delivery device, in people with type 2 diabetes

2013 ◽  
Author(s):  
J. K. Mader ◽  
L. C. Lilly ◽  
F. Aberer ◽  
J. Pachatz ◽  
S. Korsatko ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Delivery ◽  
Delivery Device ◽  
Bolus Insulin ◽  
Basal Bolus

Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens

2013 ◽  
Vol 60 (5) ◽  
pp. 249-253
Author(s):  
Irene Vinagre ◽  
Juan Sánchez-Hernández ◽  
José Luis Sánchez-Quesada ◽  
Miguel Ángel María ◽  
Alberto de Leiva ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Bolus Insulin ◽  
Basal Bolus ◽  
Term Type ◽  
Diabetes Patients

GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis

2018 ◽  
Vol 35 (1) ◽  
pp. e3082 ◽  
Author(s):  
Marco Castellana ◽  
Angelo Cignarelli ◽  
Francesco Brescia ◽  
Luigi Laviola ◽  
Francesco Giorgino
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring

2019 ◽  
Vol 14 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Ana María Gómez ◽  
Angélica Imitola Madero ◽  
Diana Cristina Henao Carrillo ◽  
Martín Rondón ◽  
Oscar Mauricio Muñoz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
General Ward ◽  
Insulin Regimen ◽  
Factors Associated ◽  
Bolus Insulin ◽  
Mean Glucose ◽  
Basal Bolus

Introduction: Continuous glucose monitoring (CGM) is a better tool to detect hyper and hypoglycemia than capillary point of care in insulin-treated patients during hospitalization. We evaluated the incidence of hypoglycemia in patients with type 2 diabetes (T2D) treated with basal bolus insulin regimen using CGM and factors associated with hypoglycemia. Methods: Post hoc analysis of a prospective cohort study. Hypoglycemia was documented in terms of incidence rate and percentage of time <54 mg/dL (3.0 mmol/L) and <70 mg/dL (3.9 mmol/L). Factors evaluated included glycemic variability analyzed during the first 6 days of basal bolus therapy. Results: A total of 34 hospitalized patients with T2D in general ward were included, with admission A1c of 9.26 ± 2.62% (76.8 ± 13 mmol/mol) and mean blood glucose of 254 ± 153 mg/dL. There were two events of hypoglycemia below 54 mg/dL (3.0 mmol/L) and 11 events below 70 mg/dL (3.9 mmol/L) with an incidence of hypoglycemic events of 0.059 and 0.323 per patient, respectively. From second to fifth day of treatment the percentage of time in range (140-180 mg/dL, 7.8-10.0 mmol/L) increased from 72.1% to 89.4%. Factors related to hypoglycemic events <70 mg/dL (3.9 mmol/L) were admission mean glucose (IRR 0.86, 95% CI 0.79, 0.95, P < .01), glycemic variability measured as CV (IRR 3.12, 95% CI 1.33, 7.61, P < .01) and SD, and duration of stay. Conclusions: Basal bolus insulin regimen is effective and the overall incidence of hypoglycemia detected by CGM is low in hospitalized patients with T2D. Increased glycemic variability as well as the decrease in mean glucose were associated with events <70 mg/dL (3.9 mmol/L).

scholarly journals U-500 Insulin as a Component of Basal Bolus Insulin Therapy in Type 2 Diabetes

2012 ◽  
Vol 14 (6) ◽  
pp. 505-507 ◽  
Author(s):  
Jolene Brown Lowery ◽  
Amy C. Donihi ◽  
Mary T. Korytkowski
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Bolus Insulin ◽  
Basal Bolus
Sign in / Sign up

Export Citation Format

Share Document